世界中医药
世界中醫藥
세계중의약
WORLD CHINESE MEDICINE
2014年
12期
1636-1639
,共4页
侯丽%许晶%王婧%郭晓青%宋延平
侯麗%許晶%王婧%郭曉青%宋延平
후려%허정%왕청%곽효청%송연평
新加良附方%新加良附方联合 5-Fu%VEGF%bFGF
新加良附方%新加良附方聯閤 5-Fu%VEGF%bFGF
신가량부방%신가량부방연합 5-Fu%VEGF%bFGF
Modified Liang-fu formula%Modified Liang-fu formula combined with 5-Fu%VEGF%bFGF
目的:观察新加良附方联合5-Fu 对荷人胃癌移植瘤裸鼠血清血管内皮生长因子(Vascular Endothelial Growth Factor, VEGF)、碱性成纤维生长因子(Basic Fibroblast Growth Factor,bFGF)水平的影响。方法:建立移植性人胃癌细胞(SGC-7901)裸鼠移植瘤模型,并将模型动物随机分为空白组、5-Fu 组及新加良附方高、中、低剂量组、联合给药组(新加良附中剂量+5-Fu 组)6组。新加良附方高、中、低剂量组给药剂量分别为10 g·d -1·kg -1、5 g·d -1·kg -1、2.5 g·d -1·kg -1;5-Fu 组给药剂量为17 mg·d -1·kg -1;空白组给予等量无菌生理盐水,新加良附方联合5-Fu 组剂量为新加良附方中剂量(5 g·d -1·kg -1)联合应用5-Fu(17 mg·d -1·kg -1)。给药结束后,采用免疫学方法(ELISA)检测裸鼠血清中 VEGF、bFGF 的含量。结果:VEGF 含量显示:联合给药组,5-Fu 组,新加良附大、中、小剂量组裸鼠血清中含量较空白对照组均明显降低(P <0.01),新加良附各剂量组对VEGF 含量减低作用具有一定的剂量依赖性,联合用药组 VEGF 含量低于5-Fu 组、新加良附中剂量组,但无统计学意义(P >0.05)。bFGF 含量显示:联合给药组,5-Fu 组,新加良附大、中、小剂量组裸鼠血清中含量较空白对照组均明显降低(P <0.01)。结论:新加良附方可以下调人胃癌裸鼠的血清中 VEGF、bFGF 表达水平,提示新加良附方具有一定抗胃癌新生血管生成作用。
目的:觀察新加良附方聯閤5-Fu 對荷人胃癌移植瘤裸鼠血清血管內皮生長因子(Vascular Endothelial Growth Factor, VEGF)、堿性成纖維生長因子(Basic Fibroblast Growth Factor,bFGF)水平的影響。方法:建立移植性人胃癌細胞(SGC-7901)裸鼠移植瘤模型,併將模型動物隨機分為空白組、5-Fu 組及新加良附方高、中、低劑量組、聯閤給藥組(新加良附中劑量+5-Fu 組)6組。新加良附方高、中、低劑量組給藥劑量分彆為10 g·d -1·kg -1、5 g·d -1·kg -1、2.5 g·d -1·kg -1;5-Fu 組給藥劑量為17 mg·d -1·kg -1;空白組給予等量無菌生理鹽水,新加良附方聯閤5-Fu 組劑量為新加良附方中劑量(5 g·d -1·kg -1)聯閤應用5-Fu(17 mg·d -1·kg -1)。給藥結束後,採用免疫學方法(ELISA)檢測裸鼠血清中 VEGF、bFGF 的含量。結果:VEGF 含量顯示:聯閤給藥組,5-Fu 組,新加良附大、中、小劑量組裸鼠血清中含量較空白對照組均明顯降低(P <0.01),新加良附各劑量組對VEGF 含量減低作用具有一定的劑量依賴性,聯閤用藥組 VEGF 含量低于5-Fu 組、新加良附中劑量組,但無統計學意義(P >0.05)。bFGF 含量顯示:聯閤給藥組,5-Fu 組,新加良附大、中、小劑量組裸鼠血清中含量較空白對照組均明顯降低(P <0.01)。結論:新加良附方可以下調人胃癌裸鼠的血清中 VEGF、bFGF 錶達水平,提示新加良附方具有一定抗胃癌新生血管生成作用。
목적:관찰신가량부방연합5-Fu 대하인위암이식류라서혈청혈관내피생장인자(Vascular Endothelial Growth Factor, VEGF)、감성성섬유생장인자(Basic Fibroblast Growth Factor,bFGF)수평적영향。방법:건립이식성인위암세포(SGC-7901)라서이식류모형,병장모형동물수궤분위공백조、5-Fu 조급신가량부방고、중、저제량조、연합급약조(신가량부중제량+5-Fu 조)6조。신가량부방고、중、저제량조급약제량분별위10 g·d -1·kg -1、5 g·d -1·kg -1、2.5 g·d -1·kg -1;5-Fu 조급약제량위17 mg·d -1·kg -1;공백조급여등량무균생리염수,신가량부방연합5-Fu 조제량위신가량부방중제량(5 g·d -1·kg -1)연합응용5-Fu(17 mg·d -1·kg -1)。급약결속후,채용면역학방법(ELISA)검측라서혈청중 VEGF、bFGF 적함량。결과:VEGF 함량현시:연합급약조,5-Fu 조,신가량부대、중、소제량조라서혈청중함량교공백대조조균명현강저(P <0.01),신가량부각제량조대VEGF 함량감저작용구유일정적제량의뢰성,연합용약조 VEGF 함량저우5-Fu 조、신가량부중제량조,단무통계학의의(P >0.05)。bFGF 함량현시:연합급약조,5-Fu 조,신가량부대、중、소제량조라서혈청중함량교공백대조조균명현강저(P <0.01)。결론:신가량부방가이하조인위암라서적혈청중 VEGF、bFGF 표체수평,제시신가량부방구유일정항위암신생혈관생성작용。
Objective:To observe the effect of Modified Liang-fu Formula (MLFF)combined with 5-Fu on VEGF and bFGF expression in the serum of human gastric cancer xenografted nude mice.Methods:The animal model of SGC-7901 xenografted nude mice was estab-lished,and all the mice were randomly divided into 6 groups;namely model control group (the same amount of normal sterile saline),5-Fu group (17 mg·d -1 ·kg -1 ),MLFF high-dose group (10 g·d -1 ·kg -1 ),MLFF medium-dose group (5 g·d -1 ·kg -1 ),MLFF low-dose group (2.5 g·d -1 ·kg -1 )and drug combination group (5 g·d -1 ·kg -1 MLFF combined with 17 mg·d -1 ·kg -1 5-Fu). After 10 days of continuous treatment,eyeball blood was withdrew,the mice were killed,and the expression of VEGF and bFGF in the se-rum were detected using ELISA method.Results:Compared to model control group,the expression levels of VEGF in nude mice serum were significantly reduced in 5-Fu group,MLFF high-dose group,MLFF medium-dose group,MLFF low-dose group and drug combination group,respectively (P <0.01),while MLFF reduced VEGF expression in a dose-dependent manner.The combination group showed a lower level of VEGF compared to 5-Fu group and MLFF medium-dose group,but there was no significant difference (P <0.05).Mean-while,compared to model control group,the expression level of bFGF in nude mice serum was significantly decreased in 5-Fu group, MLFF high-dose group,MLFF medium-dose group,MLFF low-dose group and drug combination group,respectively (P <0.01).Conclu-sion:MLFF can down-regulate the expression of VEGF,bFGF in the serum of human gastric cancer xenografted nude mice.It indicates that MLFF has the potential to serve as anti-angiogenesis agent for gastric cancer.